Preliminary observation of efficacy of MRC UKALL Ⅻ/ECOG E2993 regimen for adults with acute lymphoblastic leukemia

VernacularTitle:MRC UKALL Ⅻ/ECOG E2993方案诱导缓解成年人急性淋巴细胞白血病的初步疗效观察
Author: Jie LI ; Qirong GENG ; Guinan LIN ; Guobao WANG ; Xiaoqin CHEN ; Yue LV
Publication Type:Journal Article
Keywords: Leukemia; lymphocytic; acute; Drug therapy; combination; Treatment outcome
From: Journal of Leukemia & Lymphoma 2009;18(8):466-468
CountryChina
Language:Chinese
Abstract: Objective To observe the efficacy and adverse effects of MRC UKALL Ⅻ/ECOG E2993 regimen in inducing remission of Chinese adults with acute iymphoblastic leukemia(ALL). Methods 11 cases of previously untreated ALL patients were treated with MRC UKALL Ⅻ/ECOG E2993 regimen, then observe the efficacy and adverse effects. Results All of the 11 patients achieved complete rcmission(CR), the CR rate was 100 %. Among the 11 patients,8 patients achieved CR after the first course of chemotherapy. In the 8 patients which could be followed up, 5 patients achieved durative CR, among that the longest survival time was 30 months, and 3 patients had relapses. This regimen has a severe myelosuppression. There was an effect on liver function, mostly in the increase of glutamic-pyruvic transaminase and glutamic-oxaloacetic transaminase.After the symptomatic treatment, liver function could return to normal. No treatment-related deaths occurred. Conclusion MRC UKALL Ⅻ/ECOG E2993 regimen can be used as inducing remission therapy for Chinese adults with acute lymphoblastic leukemia.